PHIO
Phio Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
2.19 / 10
Underperform
PHIO's fundamental score is 2.2/10, reflecting subpar health. Key concerns include a negative interest coverage ratio (-59.8), signaling potential distress, and high inventory turnover (7.48) and revenue growth metrics (94.17% YoY), which are offset by weak profitability (net profit/total profit = 100%, but grouped poorly). These factors collectively suggest operational and solvency challenges that weigh heavily on the investment case.
Analysis Checks(5/5)
Total operating revenue (YoY growth rate %)
Value94.17
Score3/3
Weight-38.74%
1M Return0.88%
Value94.17
Score3/3
Weight-38.74%
1M Return0.88%
Interest coverage ratio (EBIT / Interest expense) (%)
Value-59.82
Score2/3
Weight52.06%
1M Return-1.25%
Value-59.82
Score2/3
Weight52.06%
1M Return-1.25%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight41.10%
1M Return-0.98%
Value100.00
Score2/3
Weight41.10%
1M Return-0.98%
Inventory turnover ratio
Value7.48
Score2/3
Weight49.98%
1M Return-1.23%
Value7.48
Score2/3
Weight49.98%
1M Return-1.23%
Operating revenue (YoY growth rate %)
Value87.16
Score2/3
Weight-4.39%
1M Return0.10%
Value87.16
Score2/3
Weight-4.39%
1M Return0.10%
Total operating revenue (YoY growth rate %)
Value94.17
Score3/3
Weight-38.74%
1M Return0.88%
Value94.17
Score3/3
Weight-38.74%
1M Return0.88%
Inventory turnover ratio
Value7.48
Score2/3
Weight49.98%
1M Return-1.23%
Value7.48
Score2/3
Weight49.98%
1M Return-1.23%
Interest coverage ratio (EBIT / Interest expense) (%)
Value-59.82
Score2/3
Weight52.06%
1M Return-1.25%
Value-59.82
Score2/3
Weight52.06%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value87.16
Score2/3
Weight-4.39%
1M Return0.10%
Value87.16
Score2/3
Weight-4.39%
1M Return0.10%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight41.10%
1M Return-0.98%
Value100.00
Score2/3
Weight41.10%
1M Return-0.98%
Is PHIO undervalued or overvalued?
- PHIO scores 2.19/10 on fundamentals and holds a Premium valuation at present. Backed by its -86.90% ROE, 0.00% net margin, -1.40 P/E ratio, 1.01 P/B ratio, and 77.86% earnings growth, these metrics solidify its Underperform investment rating.
